Research programme: beta-amyloid fibrillogenesis inhibitors - Elan Pharmaceuticals/NeuralabAlternative Names: beta-amyloid fibrillogenesis inhibitors research programme - Elan Pharmaceuticals/Neuralab; Research programme: amyloid-beta fibrillogenesis inhibitors - Elan Pharmaceuticals/Neuralab
Latest Information Update: 24 Jun 2003
At a glance
- Originator Elan Corporation; Neuralab
- Class Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 23 Apr 2001 Preclinical development for Alzheimer's disease in USA (Unknown route)